Following the unprecedented US Food and Drug Administration (FDA) approval of 5 new drugs over a 4-year period (2010-2013) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), it is understandable that those clinicians and investigators who focus on the management of this disease came to this year’s meeting of the American Society of Clinical Oncology (ASCO) with high expectations. The data presented at the meeting may best be characterized as providing some practice-informing data from an “older era,” with provocative early data in the area of mutational targeted therapeutics that will begin to help transform the field, which recently has been appropriately transfixed on targeting various aspects of androgen-receptor (AR) biology.
Dreicer R. Highlights in Genitourinary (Prostate) Cancer. JAMA Oncol. 2016;2(10):1257-1258. doi:10.1001/jamaoncol.2016.3325